AR and prostate carcinoma: Unfortunately, the resistance to these agents develops through mechanisms such as AR transcriptional reprogramming, AR mutations or alternative splicing, and AR‐independent lineage plasticity.[5] Notably, the incidence of neuroendocrine prostate cancer (NEPC), an even more lethal stage of prostate cancer type, has increased in the era of new ARSIs.